RxDoctor Payments Data

Giezel Rivera, OD

Optometrist · Hilo, HINPI 1710328976

Payments from drug & device makers

$3,052in general payments, 2019–2025

Across 66 payments — averaging $46.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Bausch & Lomb Americas Inc.$467
  • Johnson & Johnson Vision Care, Inc.$310
  • Glaukos Corporation$285
  • Amgen$277
  • AbbVie$276
  • plus $415 from 5 others

What the payments were for

  • Food & beverage$3,052100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,052 in reported general payments places this provider in the 70th percentile of 310 optometrist providers in Hawaii.

See all optometrist providers in Hawaii

Medicare billing

Part B allowed, 2024
$212,439
Medicare patients
930
Services billed
2,926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast25$37,497
LumiganBimatoprost28$19,587
RestasisCyclosporine13$18,731
VyzultaLatanoprostene Bunod25$10,306
LotemaxLoteprednol Etabonate15$5,309
Latanoprost161$4,494
Bepotastine Besilate19$3,051
SimbrinzaBrinzolamide/Brimonidine Tart15$2,925
Loteprednol Etabonate13$2,708
Tobramycin-DexamethasoneTobramycin/Dexamethasone35$2,219
Difluprednate13$705
Azelastine Hcl18$621
Prednisolone Acetate15$551
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat22$550
Timolol Maleate27$198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$467$47,80350 claims
AbbVieLumigan, Restasis$276$38,31841 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax, Loteprednol Etabonate$132$8,01728 claims
AlconSimbrinza$1,022$2,92515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 310 optometrist providers in Hawaii.

Other optometrist in Hilo

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →